U.S. markets closed

Lipella Pharmaceuticals Inc. (LIPO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1000-0.1100 (-4.98%)
At close: 04:00PM EDT
2.2000 +0.10 (+4.76%)
After hours: 07:44PM EDT

Lipella Pharmaceuticals Inc.

7800 Susquehanna St.
Suite 505
Pittsburgh, PA 15208
United States

Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Dr. Jonathan Kaufman M.B.A., Ph.D.Co-Founder, Chairman, CEO, Pres, Sec. & Treasurer183.3kN/A1966
Dr. Michael B. Chancellor M.D.Co-Founder, Chief Medical Officer & Director101.27kN/A1959
Mr. Douglas Johnston CPAChief Financial Officer48kN/A1985
Ms. Michele GruberDirector of OperationsN/AN/AN/A
Katie JohnstonControllerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Corporate Governance

Lipella Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.